Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose –escalation phase 1 trial

ConclusionsDostarlimab demonstrated consistent and predictable PK and associated PDy. The observed safety profile was acceptable and characteristic of the anti-PD-1 drug class.Trial registration: ClinicalTrials.gov, NCT02715284. Registration date: March 9, 2016.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research